查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2085332

細胞療法市場：按類型、治療方法、給藥途徑、應用和最終用戶分類－2026-2032年全球市場預測

Cell Therapy Market by Type, Therapy Type, Mode of Administration, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，細胞治療市場將成長至 147.3 億美元，複合年成長率為 12.59%。

主要市場統計數據
基準年 2025 64.1億美元
預計年份：2026年 72.1億美元
預測年份 2032 147.3億美元
複合年成長率 (%) 12.59%

細胞療法市場執行摘要

細胞療法正從突破性療法發展成為先進醫療保健的核心支柱，涵蓋CAR-T細胞療法、腫瘤浸潤淋巴細胞療法、造血幹細胞移植、間質幹細胞應用、誘導多功能細胞（iPS細胞）平台以及新興的同種異體細胞療法計畫。自美國FDA於2017年首次批准CAR-T細胞療法以來，監管機構已批准多種用於治療骨髓惡性腫瘤的細胞療法，而2024年美國首個用於治療進行性黑色素瘤的TIL療法的獲批，進一步凸顯了基因修飾和增殖的「活體藥物」的臨床和治療意義。

細胞治療領域的變革性變化

細胞療法的格局正從以醫院為中心的個人化治療路徑轉向能夠惠及更廣泛患者的工業化平台。自體CAR-T細胞療法仍然是血液系統惡性腫瘤臨床療效的標桿，但其漫長的靜脈間輸注時間、複雜的物流以及高昂的生產成本正在加速異體移植、體內治療和自動化生產模式的發展。

人工智慧對細胞療法的累積影響

人工智慧 (AI) 透過改善標靶發現、供體和患者分層、製程開發、品質分析和臨床試驗設計，對整個細胞治療價值鏈產生累積影響。將 AI 驅動的影像分析、多體學建模和機器學習應用於生產數據，可以幫助識別效力標誌物、預測批間差異，並在出現偏差時快速進行根本原因分析。

細胞治療的關鍵區域見解

北美仍然是細胞療法領域最成熟的地區之一，以美國主導，擁有FDA批准的CAR-T細胞療法、健全的生物技術資金籌措體系、實力雄厚的大學附屬醫療中心以及完善的專業治療網路。加拿大也在透過醫院主導的細胞療法計畫、公共研究舉措以及再生醫學領域的合作取得進展，但生產規模、與保險公司的協調以及地域覆蓋仍然是重大挑戰。

全球細胞治療市場中的關鍵群體特定洞察

歐盟和七國集團（G7）憑藉其先進的監管體系、高額的醫療保健支出、健全的智慧財產權保護、完善的藥物警戒機制以及成熟的臨床試驗網路，在細胞療法的商業化進程中發揮核心作用。這些市場往往制定了先進治療藥物（ATMP）在品質、可比較性、長期安全性追蹤、報銷機制以及衛生經濟價值證明等方面的全球標準。

主要國家細胞療法的發展趨勢

美國憑藉FDA的批准、大學附屬醫院、臨床試驗活動、專業治療網路和先進的生產能力，在全球細胞治療市場中佔據領先地位。加拿大憑藉著強大的公共研究機構、細胞治療網路和醫院項目，為此生態系統提供了有力補充。墨西哥則透過在北美的專業醫療服務、臨床能力和生產相關機遇，不斷擴大其影響力。巴西是拉丁美洲最重要的細胞治療中心，這得益於其研究型醫院、移植技術、公共醫療體系經驗以及不斷完善的腫瘤治療基礎設施。

為行業領導者提供的實用建議

產業領導者應從臨床試驗設計階段就將可生產性放在首位。具備明確療效指標、可擴展的密封生產系統、完善的身份和存儲歷史管理、檢驗的冷凍保存策略以及標準化的出貨前測試的項目，在法規核准、商業化和可靠地交付給患者方面更具優勢。

調查方法

本執行摘要採用系統性的二手研究途徑編寫，並遵循既定的市場情報分析標準。研究資料包括監管資訊披露、臨床試驗註冊數據、同行評審文獻、公共衛生機構最新動態、專利和產品核可資訊、報銷政策文件以及涵蓋細胞療法、CAR-T細胞療法、幹細胞療法、再生醫學和先進處方藥的檢驗行業資訊來源。

結論

細胞療法正進入一個關鍵階段，臨床療效檢驗、生產規模、人工智慧驅動的流程智慧以及醫保報銷機制將決定市場主導。腫瘤學仍然是該領域最強勁的驅動力，但自體免疫疾病、再生醫學、固體癌和異體移植平台的研究正在拓展先進細胞療法的長期發展機會。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 細胞療法市場：按類型分類

  • 非幹細胞
    • CAR-T細胞
    • 樹突狀細胞
    • NK細胞
  • 幹細胞
    • 胚胎幹細胞
    • 造血幹細胞
    • 間質幹細胞

第8章 細胞療法市集：依療法類型分類

  • 同種
  • 本土種植

第9章 細胞療法市場：依給藥方式分類

  • 肌肉內部
  • 腫瘤內部
  • 靜脈

第10章 細胞療法市場：依應用領域分類

  • 自體免疫疾病
    • 多發性硬化症
    • 類風濕性關節炎
  • 癌症治療
    • 骨髓惡性腫瘤
    • 固體癌
  • 感染疾病
    • 細菌感染疾病
    • 病毒感染疾病
  • 再生醫學

第11章 細胞療法市場：以最終用戶分類

  • 學術研究機構
  • 診所
  • 私人考試機構
  • 醫院

第12章 細胞療法市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 細胞療法市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 細胞療法市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Allogene Therapeutics, Inc.
  • Anterogen Co., Ltd.
  • Astellas Pharma Inc.
  • Athersys, Inc.
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • Castle Creek Biosciences, Inc.
  • Catalent, Inc.
  • FUJIFILM Holdings Corporation
  • Gilead Sciences, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • Kolon TissueGene, Inc.
  • Lonza Group Ltd.
  • Lovance Biotherapeutics, Inc.
  • Medipost Co., Ltd.
  • Mesoblast Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Sartorius AG
  • Stemedica Cell Technologies, Inc.
  • Stempeutics Research Pvt. Ltd.
  • Takeda Pharmaceutical Company Limited
  • TegoScience
  • Thermo Fisher Scientific, Inc.
  • Vericel Corporation
Product Code: MRR-433AB1DC28D4

The Cell Therapy Market is projected to grow by USD 14.73 billion at a CAGR of 12.59% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.41 billion
Estimated Year [2026] USD 7.21 billion
Forecast Year [2032] USD 14.73 billion
CAGR (%) 12.59%

Cell Therapy Market Executive Summary

Cell therapy is moving from a breakthrough modality into a core pillar of advanced healthcare, spanning CAR T-cell therapy, tumor-infiltrating lymphocyte therapy, hematopoietic stem cell transplantation, mesenchymal stromal cell applications, induced pluripotent stem cell platforms, and emerging allogeneic cell therapy programs. Since the first U.S. FDA approval of a CAR T-cell therapy in 2017, regulators have authorized multiple cellular medicines for hematologic malignancies, and the 2024 U.S. approval of the first TIL therapy for advanced melanoma further validated the clinical and therapeutic relevance of engineered and expanded living medicines.

The cell therapy market is being shaped by strong demand in oncology, rising investment in autoimmune and inflammatory disease programs, advances in cell therapy manufacturing, and the need for scalable, quality-controlled supply chains. For industry leaders, the most defensible opportunities are forming where clinical efficacy, durable patient response, manufacturing reliability, reimbursement readiness, and real-world evidence generation converge.

Transformative Shifts in the Cell Therapy Landscape

The cell therapy landscape is shifting from individualized, hospital-centered treatment pathways toward more industrialized platforms that can support broader patient access. Autologous CAR T-cell therapy remains a benchmark for clinical value in blood cancers, but long vein-to-vein timelines, complex logistics, and high production costs are accelerating development of allogeneic, in vivo, and automated manufacturing models.

Scientific progress is also widening the addressable disease base. Cell therapies are advancing beyond hematologic malignancies into solid tumors, autoimmune diseases, rare genetic disorders, regenerative medicine, and transplant-related indications. At the same time, regulators are emphasizing potency assays, comparability, long-term follow-up, and post-market safety surveillance, making evidence quality a central competitive differentiator.

Cumulative Impact of Artificial Intelligence on Cell Therapy

Artificial intelligence is becoming a cumulative force across the cell therapy value chain by improving target discovery, donor and patient stratification, process development, quality analytics, and clinical trial design. AI-enabled image analysis, multi-omics modeling, and machine learning applied to manufacturing data can help identify potency markers, predict batch variability, and support faster root-cause analysis when deviations occur.

The impact is especially important for cell therapy manufacturing, where living products are sensitive to starting material quality, culture conditions, and logistics. AI does not replace regulatory-grade validation, but it can strengthen process control, reduce failed batches, and support adaptive trial enrollment when integrated with compliant data governance, explainable models, cybersecurity controls, and human oversight.

Key Regional Insights for Cell Therapy

North America remains one of the most mature regions for cell therapy, led by the United States through FDA-approved CAR T-cell therapies, a deep biotechnology financing ecosystem, strong academic medical centers, and established specialty treatment networks. Canada is also advancing through hospital-based cell therapy programs, public research initiatives, and regenerative medicine collaborations, although manufacturing scale, payer coordination, and geographic access remain key priorities.

Europe benefits from the European Medicines Agency's advanced therapy medicinal product framework and strong translational research clusters across Germany, France, Italy, Spain, and the United Kingdom. The European Union's centralized regulatory pathway supports cross-border authorization, while country-level health technology assessment, hospital exemption practices, national pricing systems, and reimbursement processes continue to shape launch sequencing and patient access.

Asia-Pacific is expanding as China, Japan, South Korea, India, Australia, and ASEAN markets invest in regenerative medicine, oncology innovation, clinical trial capacity, and domestic manufacturing capabilities. China has built a large clinical development base for CAR T-cell therapy, Japan operates a regenerative medicine regulatory framework designed to support conditional and time-limited access, and South Korea and Australia are strengthening advanced therapy infrastructure through biomanufacturing, translational research, and internationally credible clinical trial systems.

Latin America, the Middle East, and Africa are at earlier but increasingly strategic stages of adoption. Brazil and Mexico are regional anchors for clinical research, transplant capabilities, and specialty oncology care in Latin America. GCC countries are investing in medical hubs, genomics, precision medicine infrastructure, and specialized hospitals, while African markets are gradually building capacity through oncology centers, hematopoietic stem cell transplant programs, public health partnerships, and international collaborations focused on equitable access.

Key Group Insights Across Global Cell Therapy Markets

The European Union and G7 economies are central to cell therapy commercialization because they combine advanced regulatory systems, high healthcare spending, robust intellectual property protection, established pharmacovigilance practices, and mature clinical trial networks. These markets often set global expectations for quality, comparability, long-term safety follow-up, reimbursement evidence, and health economic value demonstration for advanced therapy medicinal products.

BRICS countries are increasingly important to cell therapy development due to large patient populations, rising biomanufacturing capacity, expanding oncology infrastructure, and government support for biotechnology self-reliance. China and India are particularly influential within BRICS, with China leading in cell therapy clinical activity and India expanding cost-efficient bioprocessing, hospital networks, domestic innovation, and access-oriented treatment models.

ASEAN offers a diverse growth corridor where Singapore acts as a biomedical hub and Thailand, Malaysia, Indonesia, Vietnam, and the Philippines continue building capacity in specialty care, clinical research, and regenerative medicine services. GCC markets are investing in high-acuity medical infrastructure, genomics-led healthcare, and medical tourism capabilities, while NATO members overlap significantly with advanced North American and European research ecosystems that support resilient supply chains, clinical collaboration, quality standards, and regulatory alignment.

Key Country Insights in Cell Therapy

The United States leads the global cell therapy market through FDA approvals, academic medical centers, clinical trial activity, specialized treatment networks, and advanced manufacturing capacity. Canada complements this ecosystem with strong public research institutions, cell therapy networks, and hospital-based programs, while Mexico is gaining relevance through specialty care, clinical capabilities, and manufacturing-adjacent opportunities in North America. Brazil is Latin America's most important cell therapy hub due to its research hospitals, transplant expertise, public health system experience, and expanding oncology infrastructure.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are major centers for advanced therapy research, clinical adoption, regulatory engagement, and reimbursement evaluation. Germany and France provide strong biomanufacturing and hospital networks, the United Kingdom remains influential through innovation pathways, academic excellence, and early-access mechanisms, while Italy and Spain contribute significant transplant, oncology, and hospital-based advanced therapy expertise. Russia maintains scientific capabilities in cell-based research and transplant medicine but faces greater international collaboration, procurement, and supply chain constraints.

In Asia-Pacific, China has become a major center for CAR T-cell therapy development and clinical trials, supported by large patient access, hospital networks, and domestic innovation policies, while India is expanding affordable biotechnology platforms, stem cell research governance, and hospital-based advanced care. Japan's regenerative medicine framework and established pharmaceutical sector support translation, South Korea is investing in biomanufacturing, cell therapy startups, and regulatory modernization, and Australia provides a strong clinical trial environment, translational research networks, and high regulatory credibility.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize manufacturability as early as clinical design. Programs with clear potency assays, scalable closed-system manufacturing, robust chain-of-identity and chain-of-custody controls, validated cryopreservation strategies, and standardized release testing are better positioned for regulatory review, commercialization, and reliable patient delivery.

Organizations should also build reimbursement evidence from the start by linking clinical endpoints to durability, quality of life, hospital utilization, safety management, and total cost of care. Partnerships with academic centers, contract manufacturers, data platforms, logistics specialists, and payer stakeholders can accelerate development while reducing execution risk in a market where scientific success must be matched by operational excellence.

Research Methodology

This executive summary is developed using a structured secondary research approach aligned with established standards for market intelligence. Inputs include regulatory agency disclosures, clinical trial registries, peer-reviewed literature, public health authority updates, patent and product approval information, reimbursement policy documents, and validated industry sources covering cell therapy, CAR T-cell therapy, stem cell therapy, regenerative medicine, and advanced therapy medicinal products.

The analysis emphasizes triangulation across scientific, regulatory, commercial, manufacturing, and regional indicators. Market interpretations are derived from observable evidence such as therapy approvals, clinical development activity, manufacturing investments, reimbursement pathways, treatment infrastructure, safety requirements, and regional policy frameworks rather than unsupported claims.

Conclusion

Cell therapy is entering a decisive phase in which clinical validation, manufacturing scale, AI-enabled process intelligence, and reimbursement evidence will determine market leadership. The sector's strongest momentum remains in oncology, but autoimmune disease, regenerative medicine, solid tumor research, and allogeneic platforms are widening the long-term opportunity for advanced cellular medicines.

Organizations that combine scientific differentiation with operational discipline will be best positioned to capture value. As global regions build capacity and regulators refine expectations, the next phase of the cell therapy market will reward stakeholders that can deliver safe, effective, accessible, quality-controlled, and economically sustainable living medicines.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cell Therapy Market, by Type

  • 7.1. Non-stem Cells
    • 7.1.1. CAR-T Cells
    • 7.1.2. Dendritic Cells
    • 7.1.3. NK Cells
  • 7.2. Stem Cells
    • 7.2.1. Embryonic Stem Cells
    • 7.2.2. Hematopoietic Stem Cell
    • 7.2.3. Mesenchymal Stem Cell

8. Cell Therapy Market, by Therapy Type

  • 8.1. Allogenic
  • 8.2. Autologous

9. Cell Therapy Market, by Mode of Administration

  • 9.1. Intramuscular
  • 9.2. Intratumoral
  • 9.3. Intravenous

10. Cell Therapy Market, by Application

  • 10.1. Autoimmune Disorders
    • 10.1.1. Multiple Sclerosis
    • 10.1.2. Rheumatoid Arthritis
  • 10.2. Cancer Treatment
    • 10.2.1. Hematologic Malignancies
    • 10.2.2. Solid Tumors
  • 10.3. Infectious Diseases
    • 10.3.1. Bacterial Infections
    • 10.3.2. Viral Infections
  • 10.4. Regenerative Medicine

11. Cell Therapy Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Clinics
  • 11.3. Commercial Laboratories
  • 11.4. Hospitals

12. Cell Therapy Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Cell Therapy Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cell Therapy Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Allogene Therapeutics, Inc.
  • 16.2. Anterogen Co., Ltd.
  • 16.3. Astellas Pharma Inc.
  • 16.4. Athersys, Inc.
  • 16.5. BioNTech SE
  • 16.6. Bristol-Myers Squibb Company
  • 16.7. Castle Creek Biosciences, Inc.
  • 16.8. Catalent, Inc.
  • 16.9. FUJIFILM Holdings Corporation
  • 16.10. Gilead Sciences, Inc.
  • 16.11. JCR Pharmaceuticals Co., Ltd.
  • 16.12. Kolon TissueGene, Inc.
  • 16.13. Lonza Group Ltd.
  • 16.14. Lovance Biotherapeutics, Inc.
  • 16.15. Medipost Co., Ltd.
  • 16.16. Mesoblast Ltd.
  • 16.17. Novartis AG
  • 16.18. Pfizer Inc.
  • 16.19. Sartorius AG
  • 16.20. Stemedica Cell Technologies, Inc.
  • 16.21. Stempeutics Research Pvt. Ltd.
  • 16.22. Takeda Pharmaceutical Company Limited
  • 16.23. TegoScience
  • 16.24. Thermo Fisher Scientific, Inc.
  • 16.25. Vericel Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL THERAPY MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CELL THERAPY MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CELL THERAPY MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CELL THERAPY MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL CELL THERAPY MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CELL THERAPY MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CELL THERAPY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CELL THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NON-STEM CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NON-STEM CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NON-STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CAR-T CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CAR-T CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CAR-T CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DENDRITIC CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DENDRITIC CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DENDRITIC CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NK CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NK CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NK CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL STEM CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL STEM CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL EMBRYONIC STEM CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL EMBRYONIC STEM CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEMATOPOIETIC STEM CELL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HEMATOPOIETIC STEM CELL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEMATOPOIETIC STEM CELL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MESENCHYMAL STEM CELL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MESENCHYMAL STEM CELL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MESENCHYMAL STEM CELL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ALLOGENIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ALLOGENIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ALLOGENIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AUTOLOGOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AUTOLOGOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AUTOLOGOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INTRATUMORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTRATUMORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INTRATUMORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL COMMERCIAL LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL COMMERCIAL LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL COMMERCIAL LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. GCC CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. GCC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. GCC CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 170. GCC CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 171. GCC CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. GCC CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. GCC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. GCC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 175. GCC CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 176. GCC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 177. GCC CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. G7 CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 201. G7 CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. G7 CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 203. G7 CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 204. G7 CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. G7 CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. G7 CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. G7 CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 208. G7 CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 209. G7 CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 210. G7 CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. NATO CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. NATO CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. NATO CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 214. NATO CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 215. NATO CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. NATO CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. NATO CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 218. NATO CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 219. NATO CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 220. NATO CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 221. NATO CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. CANADA CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 235. CANADA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. CANADA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 237. CANADA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 238. CANADA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. CANADA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. CANADA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 241. CANADA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 242. CANADA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 243. CANADA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 244. CANADA CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. MEXICO CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. MEXICO CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. MEXICO CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 248. MEXICO CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 249. MEXICO CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. MEXICO CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. MEXICO CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. MEXICO CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 253. MEXICO CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 254. MEXICO CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 255. MEXICO CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. BRAZIL CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. BRAZIL CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. BRAZIL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 259. BRAZIL CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 260. BRAZIL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. BRAZIL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. BRAZIL CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 263. BRAZIL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 264. BRAZIL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 265. BRAZIL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 266. BRAZIL CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED KINGDOM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. GERMANY CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 279. GERMANY CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. GERMANY CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 281. GERMANY CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 282. GERMANY CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. GERMANY CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 284. GERMANY CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 285. GERMANY CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 286. GERMANY CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 287. GERMANY CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 288. GERMANY CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. FRANCE CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. FRANCE CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. FRANCE CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 292. FRANCE CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 293. FRANCE CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. FRANCE CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 295. FRANCE CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 296. FRANCE CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 297. FRANCE CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 298. FRANCE CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 299. FRANCE CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 300. RUSSIA CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 301. RUSSIA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. RUSSIA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 303. RUSSIA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 304. RUSSIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. RUSSIA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 306. RUSSIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 307. RUSSIA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 308. RUSSIA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 309. RUSSIA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 310. RUSSIA CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 311. ITALY CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 312. ITALY CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. ITALY CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 314. ITALY CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 315. ITALY CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 316. ITALY CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 317. ITALY CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 318. ITALY CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 319. ITALY CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 320. ITALY CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 321. ITALY CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 322. SPAIN CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 323. SPAIN CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 324. SPAIN CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 325. SPAIN CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 326. SPAIN CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 327. SPAIN CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 328. SPAIN CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 329. SPAIN CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 330. SPAIN CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 331. SPAIN CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 332. SPAIN CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 333. CHINA CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 334. CHINA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 335. CHINA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 336. CHINA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 337. CHINA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 338. CHINA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 339. CHINA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 340. CHINA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 341. CHINA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 342. CHINA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 343. CHINA CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 344. INDIA CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 345. INDIA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 346. INDIA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 347. INDIA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 348. INDIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 349. INDIA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 350. INDIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 351. INDIA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 352. INDIA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 353. INDIA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 354. INDIA CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 355. JAPAN CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 356. JAPAN CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 357. JAPAN CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 358. JAPAN CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 359. JAPAN CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 360. JAPAN CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 361. JAPAN CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 362. JAPAN CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 363. JAPAN CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 364. JAPAN CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 365. JAPAN CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 366. AUSTRALIA CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 367. AUSTRALIA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 368. AUSTRALIA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 369. AUSTRALIA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 370. AUSTRALIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 371. AUSTRALIA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 372. AUSTRALIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 373. AUSTRALIA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 374. AUSTRALIA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 375. AUSTRALIA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 376. AUSTRALIA CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 377. SOUTH KOREA CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 378. SOUTH KOREA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 379. SOUTH KOREA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 380. SOUTH KOREA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 381. SOUTH KOREA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 382. SOUTH KOREA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 383. SOUTH KOREA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 384. SOUTH KOREA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 385. SOUTH KOREA CELL THE